AI Article Synopsis

  • - Immune-checkpoint inhibitors (ICIs) have significantly improved treatment for advanced head and neck squamous cell carcinomas (HNSCCs), with 48% of patients experiencing immune-related adverse events (irAEs) like hypothyroidism, dermatitis, and hepatitis.
  • - Women had a higher incidence of irAEs, and these events led to treatment interruptions in 43% of affected patients.
  • - Patients who developed irAEs showed better treatment responses, with a 68% objective response rate compared to 39% in those without irAEs, and re-treatment after irAEs was feasible, yielding positive responses in a notable proportion of selected patients.

Article Abstract

Immune-checkpoint inhibitors (ICIs) have revolutionized treatment of metastatic head and neck squamous cell carcinomas (HNSCCs). Our goal was to assess for an association between immune-related adverse events (irAEs) and clinical outcomes for patients on ICIs. We analyzed a cohort of 110 HNSCC patients who received ICI therapy at the University of Virginia. On review, 48% of our patients experienced an irAE with the most common events being hypothyroidism (30%), dermatitis (14%) and hepatitis (11%). Women were more likely to experience irAEs. Treatment interruption/discontinuation occurred in 43% patients with irAEs. Development of irAEs was associated with superior objective response rate (68 vs. 39%,  = 0.009), with a greater rate of CR (17 vs. 5%) and PR (32 vs. 16%). Twelve patients underwent ICI re-treatment following irAE, with 17% attaining a complete disease response, 25% attaining a partial response, 33% achieving stable disease and 25% experiencing disease progression with ICI resumption. Development of irAE was associated with superior objective response rate, with a greater rate of CR and PR. ICI re-treatment following irAE was feasible in a significant proportion of patients and can be attempted in carefully selected patients, given the dearth of second-line therapies for these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492630PMC
http://dx.doi.org/10.1080/1750743X.2024.2409617DOI Listing

Publication Analysis

Top Keywords

patients
9
immune-related adverse
8
adverse events
8
squamous cell
8
associated superior
8
superior objective
8
objective response
8
response rate
8
greater rate
8
ici re-treatment
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!